Pacira Biosciences Inc
F:82P

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
F:82P
Watchlist
Price: 21.6 EUR 1.89%
Market Cap: 1B EUR

Net Margin
Pacira Biosciences Inc

3%
Current
-2%
Average
4.5%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3%
=
Net Income
21.4m
/
Revenue
716.8m

Net Margin Across Competitors

No Stocks Found

Pacira Biosciences Inc
Glance View

Market Cap
928.1m EUR
Industry
Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

82P Intrinsic Value
49.88 EUR
Undervaluation 57%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
3%
=
Net Income
21.4m
/
Revenue
716.8m
What is the Net Margin of Pacira Biosciences Inc?

Based on Pacira Biosciences Inc's most recent financial statements, the company has Net Margin of 3%.

Back to Top